MARKET

PBYI

PBYI

Puma Biotechnology Inc
NASDAQ
7.08
0.00
0.00%
Opening 10:34 05/13 EDT
OPEN
7.00
PREV CLOSE
7.08
HIGH
7.10
LOW
6.96
VOLUME
27.82K
TURNOVER
--
52 WEEK HIGH
7.90
52 WEEK LOW
2.850
MARKET CAP
360.37M
P/E (TTM)
14.84
1D
5D
1M
3M
1Y
5Y
1D
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
Simply Wall St · 2d ago
Weekly Report: what happened at PBYI last week (0504-0508)?
Weekly Report · 2d ago
Puma Biotechnology (PBYI) Net Margin Steady At 13.6% Challenges Bearish Earnings Narratives
Simply Wall St · 4d ago
Puma Biotechnology Raises Outlook Despite Q1 Reset
TipRanks · 4d ago
Puma (PBYI) Q1 2026 Earnings Call Transcript
The Motley Fool · 5d ago
Puma forecasts $202M-$206M in 2026 NERLYNX net product revenue while planning alisertib dose escalation and new Lung2 trial
Seeking Alpha · 5d ago
TD Cowen Sticks to Their Hold Rating for Puma Biotechnology (PBYI)
TipRanks · 5d ago
Puma Biotechnology reports Q1 adjusted EPS (4c) vs (10c) last year
TipRanks · 5d ago
More
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.

Webull offers Puma Biotechnology Inc stock information, including NASDAQ: PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PBYI stock methods without spending real money on the virtual paper trading platform.